Know Cancer

or
forgot password

A Phase I Dose Escalating Study Of SU014813 In Patients With Solid Tumors Not Amenable To Conventional Therapy


Phase 1
18 Years
N/A
Not Enrolling
Both
Neoplasms, Solid Tumors

Thank you

Trial Information

A Phase I Dose Escalating Study Of SU014813 In Patients With Solid Tumors Not Amenable To Conventional Therapy


Inclusion Criteria:



- Patients with a histologically proven advanced solid malignancy for which no
recognized therapy was available or for which standard therapy had failed

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- Serum albumin ≥3.0 g/dL and adequate haemopoietic, renal and liver function

Exclusion Criteria:

- Chemotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) or radiotherapy
or an investigational agent within 4 weeks before the start of study treatment

- Subjects had to have recovered from all prior treatment toxicities, except alopecia,
and from any major surgery.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Maximum Tolerated Dose (MTD)

Outcome Time Frame:

18-Nov-2008

Safety Issue:

Yes

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

Germany: Federal Institute for Drugs and Medical Devices

Study ID:

RTKD-7840-002

NCT ID:

NCT00982267

Start Date:

December 2003

Completion Date:

June 2011

Related Keywords:

  • Neoplasms
  • Solid Tumors
  • cancer
  • Neoplasms

Name

Location